- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07947056
A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Dr PK Bhavani, MBBS., MPH., PGDBEME
- Número de teléfono: 044 2836 9537
- Correo electrónico: bhavani.pk@icmr.gov.in
Copia de seguridad de contactos de estudio
- Nombre: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Número de teléfono: 044 2836 9518
- Correo electrónico: narendra.ng@icmr.gov.in
Ubicaciones de estudio
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, India, 522503
- Reclutamiento
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
Contacto:
- Dr S Sathiyanarayanan, MBBS., MD
- Número de teléfono: 08645 280021
- Correo electrónico: sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati, Assam, India, 781101
- Activo, no reclutando
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot, Gujarat, India, 360001
- Aún no reclutando
- Govt. PDU Medical College
-
Contacto:
- Dr Bhoomika Patel, MBBS., MD
- Número de teléfono: 0281 245 8337
- Correo electrónico: doctorbhoomika@gmail.com
-
Surat, Gujarat, India, 395001
- Activo, no reclutando
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400008
- Reclutamiento
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
Contacto:
- Dr Priti Meshram, MBBS., MD., DNB
- Número de teléfono: 022 2373 5555
- Correo electrónico: drpritimeshram@gmail.com
-
Nagpur, Maharashtra, India
- Aún no reclutando
- All India Institute Of Medical Sciences, Nagpur
-
Contacto:
- Dr Yogesh Bahurupi, MBBS., MD
- Número de teléfono: 0712 2352078
- Correo electrónico: dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong, Meghālaya, India, 793018
- Reclutamiento
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
Contacto:
- Dr Monaliza Lyngdoh, MBBS., MD
- Número de teléfono: 0364 2538013
- Correo electrónico: monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, India, 110030
- Aún no reclutando
- National Institute of TB and Respiratory Diseases
-
Contacto:
- Dr Jitendra Kumar Saini, MBBS., MD
- Número de teléfono: 011 2651 3325
- Correo electrónico: drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar, Odisha, India, 751019
- Activo, no reclutando
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar, Odisha, India, 751001
- Activo, no reclutando
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600031
- Reclutamiento
- ICMR - National Institute for Research in Tuberculosis
-
Contacto:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- Número de teléfono: 044 2836 9537
- Correo electrónico: bhavani.pk@icmr.gov.in
-
Contacto:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Número de teléfono: 044 2836 9518
- Correo electrónico: narendra.ng@icmr.gov.in
-
Investigador principal:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
Investigador principal:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
Sub-Investigador:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad, Telangana, India, 500038
- Reclutamiento
- Govt. General and Chest Hospital, Osmania Medical College
-
Contacto:
- Dr V Karthik, MBBS., MD
- Número de teléfono: 04083814421
- Correo electrónico: vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra, Uttar Pradesh, India, 282002
- Reclutamiento
- Sarojini Naidu Medical College
-
Contacto:
- Dr Gajendra Vikram Singh, MBBS., MD
- Número de teléfono: 0562 2260353
- Correo electrónico: drsinghgv@gmail.com
-
Allahābād, Uttar Pradesh, India, 211002
- Reclutamiento
- Moti Lal Nehru Medical College
-
Contacto:
- Dr Amitabh Das Shukla, MBBS., MD
- Número de teléfono: 0532 261 3592
- Correo electrónico: adshukla1977@gmail.com
-
Lucknow, Uttar Pradesh, India, 226003
- Reclutamiento
- King George Medical University
-
Contacto:
- Dr Rajiv Garg, MBBS., MD
- Número de teléfono: 0522 2255167
- Correo electrónico: rajivkgmc@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimental: 2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimental: 2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
Comparador activo: 2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Periodo de tiempo: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
Periodo de tiempo: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Periodo de tiempo: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Periodo de tiempo: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Periodo de tiempo: At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
Periodo de tiempo: Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
- Investigador principal: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis
Publicaciones y enlaces útiles
Publicaciones Generales
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones del Tracto Respiratorio
- Infecciones
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Infecciones por bacterias grampositivas
- Infecciones bacterianas
- Infecciones bacterianas y micosis
- Infecciones por Actinomycetales
- Infecciones por micobacterias
- Tuberculosis
- Tuberculosis Pulmonar
- Calidad, acceso y evaluación de la atención médica
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Terapéutica
- Mecanismos de evaluación de atención médica
- Calidad de la atención médica
- Compuestos policíclicos
- Compuestos heterocíclicos, 4 o más anillos
- Rifamycinas
- Lactamas, macrocíclicas
- Compuestos macrocíclicos
- Fluoroquinolonas
- 4 quinolonas
- Quinolonas
- Quinolinas
- De la ofloxacina
- Características del estudio epidemiológico
- Rifampicina
- Levofloxacina
- Protocolos clínicos
Otros números de identificación del estudio
- 2025 011
- CTRI/2026/02/102698 (Identificador de registro: CLINICAL TRIALS REGISTRY - INDIA)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .